Indication
Anktiva in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours.
Loading your page…
Marketing Authorisation Holder: Immunitybio Ireland Limited
EMA Authorisation: 16/02/2026
INN: nogapendekin alfa inbakicept
AI Drug & Interaction Analysis
Free account required
Ask Osler about Anktiva: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.